Search

Displaying results 5281 - 5290 of 9707 in total
  1. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset

  2. Drug

    Prucalopride

    go.drugbank.com/drugs/DB06480
    ApprovedInvestigational

    Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties.

  3. Drug

    Aplaviroc

    go.drugbank.com/drugs/DB06497
    Investigational

    A spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1.

  4. Drug

    Resiquimod

    go.drugbank.com/drugs/DB06530
    Investigational

    It is also being studied to find out if adding it to a tumor vaccine improves the antitumor immune response. It is a type of imidazoquinoline and a type of immunomodulator. … A substance being studied in the treatment of some types of skin cancer. When put on the skin, resiquimod causes some immune cells to make certain chemicals that may help them kill tumor cells.

  5. Drug

    Pazopanib

    go.drugbank.com/drugs/DB06589
    ApprovedInvestigational

    Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
  6. Drug

    Panobinostat

    go.drugbank.com/drugs/DB06603
    ApprovedInvestigational

    Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  7. Drug

    Mepyramine

    go.drugbank.com/drugs/DB06691
    ApprovedVet approved

    It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect.

    Mixtures: Ninjacof-A, Prefrin A Liq
  8. Drug

    Arbekacin

    go.drugbank.com/drugs/DB06696
    Investigational

    An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA).

    Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index
  9. Drug

    Dexmethylphenidate

    go.drugbank.com/drugs/DB06701
    ApprovedInvestigational

    The d-isomer is thought to have greater effect with fewer side effects than the l-isomer or the racemic mixture[A177181]. … It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant[A177193]. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD)[Label,A177181].

  10. Drug

    Iobenguane

    go.drugbank.com/drugs/DB06704
    ApprovedInvestigational

    Iodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved on September 19, 2008.

    Categories: Compounds used in a research, industrial, or household setting